Zyneyro

Zyneyro is a preclinical-stage biotech developing first-in-class peptide therapeutics for chronic pain by targeting the protein PICK1, a novel mechanism identified through foundational academic research. The company's lead candidate, ZYNPN, has demonstrated efficacy in multiple preclinical pain models without impairing normal pain perception or cognitive function, positioning it as a potential non-opioid alternative. Founded by University of Copenhagen neuroscientists and backed by a strong scientific advisory board, Zyneyro is advancing towards first-in-human studies. The company operates as a private, pre-revenue entity targeting the large and underserved neuropathic pain market.

Proprietary synthetic peptides designed to inhibit the protein PICK1, a molecular scaffold critical for maladaptive neural plasticity in chronic pain.

The chronic pain market is crowded with generics and novel mechanisms, but Zyneyro's specific targeting of PICK1 appears to be a first-in-class approach. It competes with other non-opioid drug developers, neuromodulation devices, and digital therapeutics, differentiating itself through a target focused on the root cause of maladaptive plasticity.